Multiple sclerosis is a chronic and often disabling disease of the nervous system, affecting about 1 million people worldwide. Even though it has been known for over a hundred years, no cause or cure has yet been discovered-but now there is hope. New therapies have been shown to slow the disease progress in some patients, and the pace of discoveries about the cellular machinery of the brain and spinal cord has accelerated. This book presents a comprehensive overview of multiple sclerosis today, as researchers seek to understand its processes, develop therapies that will slow or halt the disease and perhaps repair damage, offer relief for specific symptoms, and improve the abilities of MS patients to function in their daily lives. The panel reviews existing knowledge and identifies key research questions, focusing on: Research strategies that have the greatest potential to understand the bio- logical mechanisms of recovery and to translate findings into specific strategies for therapy. How people adapt to MS and the research needed to improve the lives of people with MS. Management of disease symptoms (cognitive impairment, depression, spasticity, vision problems, and others). The committee also discusses ways to build and financially support the MS research enterprise, including a look at challenges inherent in designing clinical trials. This book will be important to MS researchers, research funders, health care advocates for MS research and treatment, and interested patients and their families.
This book comprehensively reviews the current state of clinical trial methods in multiple sclerosis treatment, providing investigators, sponsors and specialists with current knowledge of outcome measures and study designs for disease and symptom management. The status of the rapidly evolving field of disease-modifying drugs is presented, with emphasis on the most promising therapies currently being tested. Experts discuss disease and symptom management for MS subtypes, including neuromyelitis optica and pediatric MS. In addition, key scientific advances in MS pathology, genetics, immunology and epidemiology are presented. The fourth edition has been extensively revised, featuring more than 50% new material. All chapters have been substantially updated to provide current information on rapidly evolving topics and this volume contains 15 new chapters, reflecting the growth of the field in recent years. This book is an essential reference for practitioners caring for MS patients, investigators planning or conducting clinical trials, and clinical trial sponsors.
The textbook's original structure has not changed. It remains anchored in the methods that neurologists utilize on a daily basis to approach, diagnose, and treat patients.
Multiple Sclerosis-MS-strikes about one in a thousand North Americans, usually in early adulthood, when they are building careers and starting families. In the wholly revised and updated edition of Multiple Sclerosis: The Facts You Need, readers will find a fact-filled, comprehensive guide to living with MS. The accessible text is supported by diagrams, case histories, a drug table and an extensive list of helpful books and organizations. Topics include: what MS is, and who gets it; how MS is diagnosed as 'possible,' 'probable' or 'definite'; why the disease affects different people in different ways; how 'relapsing-remitting' MS differs from 'progressive' MS; how people with MS, and their families, can adapt their homes, careers and lifestyles to cope with the disease; which treatments work, which don't and what is on the horizon. This edition of Multiple Sclerosis has been revised to incorporate new findings related to the diagnosis and treatment of MS, including very early as well as more advanced disease. Additional information has also been included on the treatment of fatigue among other symptoms.
This excellent book provides a fresh approach to multiple sclerosis, detailing the newest developments in a lively style. Particular emphasis is placed on areas of controversy and uncertainty The information conveyed is accessible to all practitioners in the field of multiple sclerosis.
This book examines the role of neurons in multiple sclerosis (MS) and the changes that occur in neurons as a result of MS. It places MS in a new and important perspective that not only explains the basis for symptom production, remission, and progress in MS, but also promises to open up new therapeutic possibilities. * Brings together the latest information from clinical, pathological, imaging, molecular, and pharmacological realms to explore the neurobiology of Multiple Sclerosis * Places MS in a new and important perspective that promises to open up new therapeutic avenues * Superbly illustrated and referenced
Progressive multiple sclerosis places a huge burden on individuals, carers and society and treatment options are currently limited. However, there have been significant recent advances in understanding progressive disease and this book draws the field together into a single, accessible, clinically focused text. Progressive Multiple Sclerosis sets out the basic science, pathology, epidemiology and treatment possibilities in progressive multiple sclerosis. The biological processes underlying disease progression are elucidated as are specific pathophysiological mechanisms. The basic science of axonal degeneration and the clinical understanding of progressive multiple sclerosis are discussed in the context of emerging and future therapies for disease progression as are trials which might be conducted for progressive multiple sclerosis. An overview of biomarkers for the disease is included and existing symptomatic therapies for progressive multiple sclerosis are covered in detail. Each chapter addresses specific aspects of progressive multiple sclerosis providing an extensive review of the current literature and a discussion of the likely mechanisms of tissue injury relevant to the disease. Progressive Multiple Sclerosis is ideal for both general neurologists and those with a specialist interest in multiple sclerosis. It will also be of interest to neurologists in training and other medical professionals treating this common disease. Dr Alastair Wilkins is Senior Lecturer in Neurology, University of Bristol, and Consultant Neurologist at Frenchay Hospital, Bristol, UK. He researches axonal injury in multiple sclerosis and related disorders.
A synthesis of current concepts about the evaluation, treatment, and future directions in MS. On the evaluation side, the authors review the use of MRI, magnetic resonance spectroscopy, functional MRI, and three-dimensional MRI, and consider the rapidly developing body of pathologic information they have yielded. On the treatment side, the focus is on recently approved medications (Novantrone), new indications for medications (CHAMPS Trial), medications in development (Oral Interferon Tau, Oral Copaxone, and Oral Cellcept), immunosuppressive therapy for both progressive disease and symptomatic therapy; the current medications for treating relapsing-remitting MS (Avonex, Betaseron, and Copaxone) are also discussed. For future directions, the authors present the current best thinking, as well as the latest discoveries in immunology relating to MS, including groundbreaking B-cell research and its applications to specific immunotherapies, and the use of immune markers for tracking the disease.
Multiple Sclerosis 3 emphasizes the latest in the pharmacologic treatment of this incurable inflammatory demyelinating disorder. Primary editors Claudia Lucchinetti, MD, and Reinhard Hohlfeld, MD, with the aid of all new contributors, present a complete and current reference on multiple sclerosis that includes discussions of such hot topics as Biomarkers, Genomics, and Surrogate Outcomes in MS; Pediatric MS; Transverse Myelitis; Attack Therapies in MS; Current Disease-Modifying Therapeutic Strategies in MS; Management of Aggressive MS; Symptomatic Therapies in MS; Complementary and Alternative Medical Therapies; and Strategies to Promote Neuroprotection and Repair. Distinguish between MS and other similar demyelinating disorders and know the best and most aggressive methods of treatment. This title in the Blue Books of Neurology series is exactly what you need to treat the disease and its relapses. Covers the latest clinical advances and relevant discussions—Biomarkers, Genomics, and Surrogate Outcomes in MS; Pediatric MS; Transverse Myelitis; Attack Therapies in MS; Current Disease-Modifying Therapeutic Strategies in MS; Management of Aggressive MS; Symptomatic Therapies in MS; Complementary and Alternative Medical Therapies; and Strategies to Promote Neuroprotection and Repair—to bring you up to date and keep your practice state-of-the-art. Features a greater emphasis on practical management to help you determine the type of multiple sclerosis and the best course of therapy. Focuses on pharmaceutical therapies so you know the best and most aggressive methods and which drugs to use for treatment. Includes extensive information on differential diagnosis so that you can clearly distinguish between multiple sclerosis and other similar demyelinating disorders. Presents expert new editors and experienced contributing authors for the most current and relevant practice information. Emphasizes the pharmacologic management of patients with multiple sclerosis to address treating the actual disease and its relapses as well as treating the symptoms.
Multiple Sclerosis (MS) is generally understood to be an inflammatory autoimmune disease of the central nervous system. While we still are not certain of the root cause of MS, research results suggest that unknown environmental factors and the presence of specific genes seem the most probable targets. MS causes an inflammatory response in the central nervous system leading to neurodegeneration, oligodendrocyte death, axonal damage, and gliosis. Over the past five years ongoing research has greatly expanded our understanding of the pathogenesis of MS, detailed insight into the epidemiology and genetic factors related to MS, the introduction of new technologies and tests to better diagnose and predict the future course of the disease and the introduction of new treatments targeting MS. This collection of review chapters provides a comprehensive reference into the science and clinical applications of the latest Multiple Sclerosis research and will be a valuable resource for the neuroscience research community and the clinical neurology community of researchers and practitioners. A comprehensive tutorial reference detailing our current foundational understanding of Multiple Sclerosis Includes chapters on key topics including the genetics of MS, MRI imaging and MS, and the latest treatment options Each chapter is translational and focuses on current research and impact on diagnosis and treatment options
|Author||: Ruth Arnon,Ariel Miller|
|Publisher||: Academic Press|
|Release Date||: 2016-05-10|
|ISBN 10||: 0128020075|
|Pages||: 502 pages|
Multiple sclerosis (MS) is the most common disabling neurological disease of young adults. More than 2.3 million people are affected by MS worldwide. Symptoms can vary widely, depending on the localization and amount of the damage induced by combined inflammatory, demyelinating, and neurodegenerative processes. Although a cure for MS does not currently exist, therapies can help treat MS attacks, attenuate disease activity, reduce progress of the disease, and manage symptoms. Translational Neuroimmunology in Multiple Sclerosis provides an overview of recent findings and knowledge of the neuroimmunology of multiple sclerosis, from experimental models and the human disease to the translation of this research to immunotherapeutic strategies. Chapters describe genetic and environmental factors underlying the disease pathogenesis of MS as a basis for development of immunotherapies, immunological markers of disease activity, pharmacogenetics, and responses to therapy. Immunomodulatory therapies currently in practice and future therapeutic strategies on the horizon—such as neuroprotective strategies, stem cells, and repair promotion—are discussed. Contributed by renowned leaders in the field, this cross-disciplinary volume is a great resource for basic scientists and clinical practitioners in neuroscience, neurology, immunology, pharmacology, and in-drug development. Provides an overview of recent findings and knowledge of the neuroimmunology of multiple sclerosis and the translation of this research to immunotherapy treatment Edited by renowned leaders in the field of neuroimmunology and multiple sclerosis Contains the latest resource material for basic and clinical scientists and practitioners in neuroscience, neurology, immunology, and pharmacology